Investor Newsletter

Issue 02 2022

MicroPort®



Firehawk Liberty™ Receives Registration Approval in Egypt

The Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System (Firehawk Liberty™), developed by Shanghai MicroPort Medical Group Co., Ltd. (MicroPort®), recently received registration approval from the Central Administration for Pharmaceutical Affairs (CAPA) of Egypt. This is the second coronary product developed by MicroPort® to be approved in Egypt since it entered into the Egyptian market with the Firehawk Rapamycin Target Eluting Coronary Stent System in November 2019.

Egypt is the third largest economy in Africa and an important hub country along the "Belt and Road" initiative. Firehawk Liberty™ is currently approved in a number of countries and regions, including Belarus, Saudi Arabia, South Korea, Brazil, Colombia, India and the European Union. In the future, MicroPort® will continue to adhere to its brand philosophy of 'The Patient Always Comes First' and work towards introducing more innovative medical devices to local markets to benefit patients around the world.

MicroPort

Firehawk®, Foxtrot® NC and Foxtrot® Pro PTCA Balloon Catheters Receive Approval in Kyrgyzstan

Shanghai MicroPort Medical (Group) Co., Ltd. (MicroPort®) has recently received registration approval from the Kyrgyzstan Department of Medicines and Medical Devices for three of its proprietary products: the Firehawk® Rapamycin Target Eluting Coronary Stent System (Firehawk®), Foxtrot® NC PTCA Balloon Catheter (Foxtrot® NC), and Foxtrot® Pro PTCA Coronary Balloon Catheter (Foxtrot® Pro).

The approval in Kyrgyzstan of these three outstanding products offered by MicroPort® fully demonstrates the company's excellent product portfolio in the field of coronary intervention, further expanding the company's global presence. In the future, MicroPort® will continue to pursue an innovative, people-centered culture to provide patients and physicians around the world with higher-quality, innovative high-end medical devices and integrated solutions.



MicroPort

First Clinical Implantation of Endovastec™'s Hercules®-LP Thoracic Stent Graft System Completed in India

Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec™) has completed the first clinical implantation of its independently developed Hercules® Low Profile Thoracic Stent Graft and Delivery System (Hercules®-LP Stent Graft System) in India. This is the first product from Endovastec™ which has been approved for marketing and used in a clinical setting in India, the thirteenth market for the Hercules®-LP Stent System, following China, Brazil, Italy, the United Kingdom, and Turkey.

Independently developed by Endovastec™, the Hercules®-LP Stent Graft System was approved for registration by the Central Drugs Standard Control Organization (CDSCO) in India in late 2021. As the world's fifth largest economy and the second most populous country in the world with a population of 1.4 billion people, India has a growing demand for medical technology and medical services, indicating huge market potential.

MicroPort NeuroTech™ NUMEN® Coil Embolization System Listed for Reimbursement under Korea's National Health Insurance System

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has announced that its independently-developed NUMEN® Coil Embolization System (NUMEN®) has received approval by Korea's Health Insurance Review and Assessment Service (HIRA) as a product eligible for health insurance reimbursement in Korea.

NUMEN® was approved for marketing in China in 2020. It received the CE Marking in Europe, registration permission from Ministry of Food and Drug Safety (MFDS) in Korea and approval from the Food and Drug Administration (FDA) in the United States in 2021. The first overseas implantation of NUMEN® was completed in August 2021 and healthcare professionals praised its stable performance and positive clinical outcomes. The approval of NUMEN® to be listed for reimbursement under the Korean national health insurance system is a crucial step in MicroPort NeuroTech™'s entry into the Korean market and its continued expansion in the international market.



MicroPort

MicroPort NeuroTech™ Receives NMPA Marketing Approval for its NUMEN Silk® 3-D Coil Embolization System

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has received marketing approval from China's National Medical Products Administration (NMPA) for its independently-developed NUMEN Silk® 3-D Electronically Detachable Coil Embolization System (NUMEN Silk®).

The approval of NUMEN Silk® in China demonstrates MicroPort NeuroTech™'s capacity to iterate and improve products quickly, resulting in safer and more effective therapeutic options for hemorrhagic stroke treatment.

MicroPort

MicroPort NeuroTech™ Obtains NMPA Marketing Approval for its Neurohawk® Stent Thrombectomy Device

MicroPort NeuroTech Limited (MicroPort NeuroTech™) has recently received marketing approval from China's National Medical Products Administration (NMPA) for its self-developed Neurohawk® Stent Thrombectomy Device (Neurohawk®).

Mr. Zhiyong Xie, President of MicroPort NeuroTech™, said, "Large vessel occlusions are a kind of severe acute ischemic stroke that can induce significant cerebral infarction with severe sequelae and a high mortality. Neurohawk® is the first clot stent retriever launched by MicroPort NueroTech™, as well as the first NMPA-approved product in our total solution for acute ischemic stroke treatment. We are excited that Neurohawk® will help more patients who are suffering from acute ischemic stroke to regain their health. Meanwhile, MicroPort NeuroTech™ will continue to improve its portfolio of products for hemorrhage stroke, acute ischemia stroke and cerebral atherosclerotic stenosis, and provide more top-quality, accessible and comprehensive solutions for stroke treatment."

MicroPort

CardioFlow Medtech Launches Prospective Multicenter Study on VitaFlow Liberty™ for Severe Aortic Valve Insufficiency

MicroPort CardioFlow Medtech Corporation (CardioFlow Medtech) has recently launched a prospective multicenter post-marketing clinical study on the treatment of severe aortic valve insufficiency using its VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™).

The study aims to observe and evaluate the safety and efficacy of VitaFlow Liberty™ in the treatment of severe aortic valve insufficiency in the real world. It is being led by the Union Hospital of Tongji Medical School, Huazhong University of Science and Technology (Wuhan Union Hospital), with the participation of leading cardiovascular centers across China, Prof. Nianguo Dong of Wuhan Union Hospital serving as the principal investigator (PI) of the study. This study will also undertake a five-year post-operative follow-up of patients implanted with VitaFlow Liberty™ to evaluate the medium-to-long term performance of the retrievable aortic valve and retrievable delivery system.



MicroPort

MicroPort® MedBot®
Announces Inclusion in Hang Seng Composite Index

Shanghai MicroPort MedBot (Group) Co., Ltd. (MicroPort® MedBot®) has announced the company has been selected for inclusion in the Hang Seng Composite Index. This inclusion will take effect on Monday, 7 March, 2022.

This inclusion reflects the capital market's recognition and confidence in the development prospects of MicroPort® MedBot®, which will help the company achieve a more diversified shareholder base. At the same time, the entry of MicroPort® MedBot® onto the Hong Kong Stock Connect list also creates a new channel for mainland investors to invest in the company's shares.

恒生指數
HANG SENG INDEXES

MicroPort

MicroPort® Urocare Obtains NMPA Marketing Approval for Ruyi Clip

MicroPort Urocare Medical Technology (Jiaxing) Co., Ltd. (MicroPort® Urocare) has received marketing approval from China's National Medical Products Administration (NMPA) for its independently-developed single-use hemostatic clip device, the Ruyi Clip. This is MicroPort® Urocare's first Class III medical device approved for use in the Gastronintestinal (GI) tract and is also the world's first hemostatic clip for large wound closure used in the GI tract.

Mr. Yiyun Que, Senior Vice President of Intelligent Manufacturing and Global Supply Chain at MicroPort®, and Chairman of MicroPort® Urocare, stated, "The Ruyi Clip is a device developed independently by MicroPort® Urocare in close collaboration with clinicians. It comes from clinical practice and serves clinical needs and marks a significant achievement in the field of gastrointestinal endoscopic therapy. Since its establishment, MicroPort® Urocare has been powered by R&D innovation and driven by clinical needs. By adhering to a diversified strategy, it dedicates itself to the field of non-vascular intervention and surgeries, covering various areas such as urology, respiratory, gastroenterology and gynecology. MicroPort® Urocare will continue to improve communication and collaboration with clinicians, innovate and develop around clinical pain points and challenges, deliver more high-quality products to meet clinical needs, and provide inclusive and total medical solutions for non-vascular interventional treatment."

Investor Newsletter

Issue 02 2022

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com